DEUCRAVACITINIB for Palmoplantar pustulosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where DEUCRAVACITINIB was used for Palmoplantar pustulosis.
Most Reported Side Effects for DEUCRAVACITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 228 | 9.6% | 0 | 1 |
| Acne | 225 | 9.4% | 0 | 1 |
| Pruritus | 187 | 7.8% | 0 | 2 |
| Rash | 175 | 7.3% | 0 | 0 |
| Erythema | 124 | 5.2% | 0 | 2 |
| Psoriasis | 122 | 5.1% | 0 | 2 |
| Off label use | 101 | 4.2% | 1 | 6 |
| Adverse event | 74 | 3.1% | 0 | 0 |
| Mouth ulceration | 72 | 3.0% | 0 | 1 |
| Folliculitis | 65 | 2.7% | 0 | 2 |
| Headache | 65 | 2.7% | 0 | 0 |
| Product dose omission issue | 61 | 2.6% | 0 | 0 |
| Pain | 60 | 2.5% | 0 | 1 |
| Skin burning sensation | 60 | 2.5% | 0 | 1 |
| Diarrhoea | 46 | 1.9% | 1 | 3 |
Other Indications for DEUCRAVACITINIB
Psoriasis (1,456)
Product used for unknown indication (808)
Psoriatic arthropathy (41)
Eczema (10)
Pustular psoriasis (10)
Guttate psoriasis (9)
Dermatitis atopic (8)
Dermatitis (5)
Erythrodermic psoriasis (5)
Granuloma annulare (5)
Other Drugs Used for Palmoplantar pustulosis
APREMILAST (226)
GUSELKUMAB (72)
SECUKINUMAB (56)
IXEKIZUMAB (40)
RISANKIZUMAB-RZAA (37)
METHOTREXATE (24)
ADALIMUMAB (21)
DUPILUMAB (20)
ETANERCEPT (18)
USTEKINUMAB (17)